Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
1 hedge funds and large institutions have $74 invested in Oncternal Therapeutics, Inc. Common Stock in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
56% less capital invested
Capital invested by funds: $169 → $74 (-$95)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$96 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
UBP
1
Union Bancaire Privee
Geneva 1,
Switzerland
| $74 | – | – | – |
|
|
2
BNP Paribas Financial Markets
Paris,
France
| – | -$96 | -182 | Closed |
|
ONCT Hedge Fund Activity: Q1 2026 in Review
1 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2026, worth a combined $74 — down 56% from $169 a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ONCT and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was BNP Paribas Financial Markets, exiting entirely with an estimated $96 sold.
- 1 institutional investor held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2026, down from 2 in Q4 2025.
- Funds reported $74 of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2026, down 56% quarter-over-quarter.
- 0 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2026 and 1 closed out, a net change of -1 holder.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2026 was BNP Paribas Financial Markets, an estimated $96 sold.
Based on aggregated 13F filings for Q1 2026.